NIHON CHOUZAI Co., Ltd., headquartered in Japan, is a leading player in the pharmaceutical industry, specialising in the provision of comprehensive healthcare solutions. Founded in 2000, the company has established a strong presence across various regions in Japan, focusing on the development and distribution of prescription medications and healthcare services. With a commitment to innovation, NIHON CHOUZAI offers unique products that cater to the evolving needs of patients and healthcare providers. Their core services include pharmacy operations, drug dispensing, and health management, all designed to enhance patient care and streamline healthcare delivery. Recognised for its market leadership, NIHON CHOUZAI has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector. The company's dedication to quality and service excellence continues to drive its success in the competitive pharmaceutical landscape.
How does NIHON CHOUZAI Co.,Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
NIHON CHOUZAI Co.,Ltd.'s score of 56 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, NIHON CHOUZAI Co., Ltd. reported total carbon emissions of approximately 698,000,000 kg CO2e, comprising 4,987,000 kg CO2e from Scope 1, 23,185,000 kg CO2e from Scope 2, and a significant 686,207,000 kg CO2e from Scope 3 emissions. This marks a slight increase in emissions compared to 2023, where total emissions were about 649,305,000 kg CO2e, with Scope 1 and Scope 2 emissions at 5,175,000 kg CO2e and 25,086,000 kg CO2e, respectively. Over the past few years, the company has seen fluctuations in its emissions. In 2022, total emissions were approximately 659,942,000 kg CO2e, with Scope 1 and Scope 2 emissions at 5,454,000 kg CO2e and 31,612,000 kg CO2e, respectively. The trend indicates a need for enhanced climate action, particularly in reducing Scope 3 emissions, which represent the largest portion of their carbon footprint. Currently, NIHON CHOUZAI has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company is not reported to inherit emissions data from any parent organisation, maintaining its own emissions reporting and performance metrics. As a key player in the pharmaceutical industry, NIHON CHOUZAI's emissions profile highlights the importance of addressing carbon emissions comprehensively, particularly in Scope 3, to align with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 6,011,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 32,782,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
NIHON CHOUZAI Co.,Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
